Edwards extends heart valve trial
This article was originally published in The Gray Sheet
Executive SummaryFirm will expand U.S. feasibility trial for its Cribier-Edwards percutaneous aortic heart valve by 35 patients before initiating a pivotal trial. Discussion with FDA about the pivotal trial design continues, but the study will not begin until all 55 patients in the current study complete six-month follow-up, according to the firm. Edwards expects a CE mark based on an ongoing European study by the end of 2007...
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.